US201 Study: A Phase 2, Randomized Proof-of-Concept Trial of Favipiravir for the Treatment of COVID-19

BACKGROUND: Favipiravir is used to treat influenza, and studies demonstrate that it has antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). METHODS: We performed a randomized, open-label, multicenter, phase 2 proof-of-concept trial of favipiravir in hospitalized...

Descripción completa

Detalles Bibliográficos
Autores principales: Finberg, Robert W, Ashraf, Madiha, Julg, Boris, Ayoade, Folusakin, Marathe, Jai G, Issa, Nicolas C, Wang, Jennifer P, Jaijakul, Siraya, Baden, Lindsey R, Epstein, Carol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Major Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8651156/
https://www.ncbi.nlm.nih.gov/pubmed/34888401
http://dx.doi.org/10.1093/ofid/ofab563

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8651156/
https://www.ncbi.nlm.nih.gov/pubmed/34888401
http://dx.doi.org/10.1093/ofid/ofab563

Ejemplares similares